Compare Tilray Brands Inc (TLRY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tilray Brands Inc vs GeneDx Holdings Corp — how do they compare? Tilray Brands Inc trades at $4.75 (market cap $649.42M), while GeneDx Holdings Corp trades at $82.37 (market cap $2.44B). The key difference: GeneDx Holdings Corp is far larger — about 3.8× Tilray Brands Inc's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| TLRY | WGS | |
|---|---|---|
Market Cap | $649.42M | $2.44B |
Sector | Health | Technology |
52-Week High | $21.00 | $167.51 |
52-Week Low | $3.88 | $34.51 |
Enterprise Value | $816.55M | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $4.77, up 7.92% in the last session, with a bullish technical signal from moving averages but mixed oscillators. The company reported record fiscal 2026 revenue of $915 million (GlobeNewsWire, July 28, 2026) but posted a net loss. Key financials show a low P/S of 0.58 and P/B of 0.4, yet profitability remains challenged with negative net income margins and ROE.
Outlook is cautiously optimistic due to revenue growth and diversification into beverages and wellness, but high execution risk persists from consistent losses and competitive pressures. Analyst sentiment is mixed with 25% buy ratings, suggesting potential upside if profitability improves, though near-term volatility is likely.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
